Tedizolid Phosphate
Tedizolid phosphate is a prodrug that is converted in vivo to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, preventing formation of the 70S initiation complex. It is approved for the treatment of acute bacterial skin and skin structure infections caused by gram-positive organisms including MRSA and is under investigation for tuberculosis. Its once-daily dosing and reduced myelosuppression compared to linezolid represent clinical advantages.
Khối lượng phân tử
450,3000 g/mol
LogP
0,30
TPSA
153,00 Ų
Lipinski RO5
Đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1
InChI
InChI=1S/C17H16FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H2,26,27,28)/t12-/m1/s1
Molecular Formula
C17H16FN6O6P
HBD / HBA
2 / 11
Liên kết có thể quay
6
Nguyên tử nặng
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
Tedizolid phosphate is a prodrug that is converted in vivo to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, preventing formation of the 70S initiation complex. It is approved for the treatment of acute bacterial skin and skin structure infections caused by gram-positive organisms including MRSA and is under investigation for tuberculosis. Its once-daily dosing and reduced myelosuppression compared to linezolid represent clinical advantages.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Tedizolid Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105669. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11476460. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tedizolid-phosphate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tedizolid-phosphate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tedizolid-phosphate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tedizolid-phosphate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tedizolid-phosphate"></drugfyi-drug>